Search / Trial NCT00000701

A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of June 14, 2024

Completed

Keywords

Drug Evaluation Acquired Immunodeficiency Syndrome Aids Related Complex Zidovudine

Description

The effects of any drug, the way a drug enters the bloodstream, the way it is used by the body, and the way the body eliminates the drug may be very different in children compared with adults. The largest group of children who have AIDS are those who are less than 2 years of age. AIDS is often first identified in infants who are about 6 months old. Studies of AZT show that it might be useful in the treatment of AIDS. Thus it is important to study the effects of the drug in children. Patients are hospitalized for 8 weeks to receive AZT through the intravenous (IV) route at 1 of 2 doses. Pat...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Treatment:
  • Allowed:
  • Nutritional support not exceeding 120 calories/kg/day (hyperalimentation or dietary supplements including vitamin, folate, iron supplements).
  • Exclusion Criteria
  • Co-existing Condition:
  • Children with the following conditions are excluded:
  • Asymptomatic with T-lymphocyte deficiency.
  • Asymptomatic viremic patients or those not meeting definition criteria of AIDS related complex (ARC) or AIDS.
  • Clinical evidence of active infection of acute nature or active significant or clinically apparent opportunistic infection at time of entry into study.
  • Hemoglobinopathy including sickle cell anemia.
  • Congenital infections such as toxoplasmosis or herpes simplex virus infection in the first month after birth or cytomegalovirus infection in the first 6 months after birth.
  • Children with the following conditions are excluded:
  • Asymptomatic with T-lymphocyte deficiency.
  • Asymptomatic viremic patients or those not meeting definition criteria of AIDS related complex (ARC) or AIDS.
  • Clinical evidence of active infection of acute nature or active significant or clinically apparent opportunistic infection at time of entry into study.
  • Hemoglobinopathy including sickle cell anemia.
  • Congenital infections such as toxoplasmosis or herpes simplex virus infection in the first month after birth or cytomegalovirus infection in the first 6 months after birth.
  • Prior Medication:
  • Excluded:
  • Suramin.
  • Ribavirin.
  • HPA 23.
  • Phosphonoformate.
  • Ansamycin.
  • Interleukin 2.
  • Interferon.
  • Excluded within 30 days of study entry:
  • All cytolytic chemotherapeutic agents, immunomodulating agents including steroids and immunoglobulin preparations.
  • Antivirals (acyclovir, ganciclovir).
  • Prior Treatment:
  • Excluded within 4 weeks of study entry:
  • Lymphocyte transfusions for immune reconstitution.
  • Excluded within 3 months of study entry:
  • Bone marrow transplant.
  • Child who is seropositive for HIV antibody or has HIV viremia and presents with one or more of following clinical criteria and at least one of the laboratory criteria may be considered an ARC patient for purpose of study:
  • Clinical criteria:
  • Persistent oral candidiasis despite appropriate therapy.
  • Wasting syndrome characterized by failure to thrive and malnutrition.
  • Recurrent or chronic unexplained diarrhea.
  • Lymphadenopathy (more than 1 cm) at 2 or more noncontiguous sites.
  • Hepatomegaly with or without splenomegaly.
  • Encephalopathy with loss of developmental milestones and cortical atrophy present on computed tomography (CT) examination.
  • Recurrent bacterial infections (bacteremia, pneumonia, septic arthritis, meningitis).
  • Cutaneous anergy as defined by lack of delayed cutaneous hypersensitivity to selected antigens.
  • Laboratory criteria:
  • Hypergammaglobulinemia (IgG or IgA) defined as immunoglobulin values exceeding the maximum age-adjusted level.
  • Decreased number of total T-lymphocytes (2 SD from mean).
  • Absolute depression in T-helper cells to less than 500/mm3.
  • Depressed (equal to or more than 2 SD from normal mean) in vitro mitogen response to at least one antigen.
  • One positive HIV culture within 3 months of study entry into the study or blood obtained and culture pending.
  • Life expectancy greater than 6 months.
  • Ambulatory and free of opportunistic infection at time of entry.
  • Reliably diagnosed disease at least moderately indicative of underlying cellular immunodeficiency and no known cause of underlying cellular immunodeficiency or other reduced resistance reported to be associated with that disease.
  • Disease accepted as sufficiently indicative of underlying cellular immunodeficiency by CDC. In absence of these opportunistic diseases, a histologically confirmed diagnosis of chronic lymphoid interstitial pneumonitis will be considered indicative of AIDS unless test(s) for HIV are negative.

Attachments

readout_NCT00000701_2024-06-14.pdf

4.5 MB

NCT00000701_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Durham, North Carolina, United States

Miami, Florida, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0